Mare Lydia, Trinchera Marco
Department of Biomedical Sciences Experimental and Clinical (DSBSC), University of Insubria, Varese, Italy.
Eur J Biochem. 2004 Jan;271(1):186-94. doi: 10.1046/j.1432-1033.2003.03919.x.
We investigated the role of beta 3 Gal-T5, a member of the beta 1,3galactosyltransferase (beta 1,3Gal-T) family, in cancer-associated glycosylation, focusing on the expression of sialyl-Lewis a (sLea, the epitope of CA19.9 antigen), poly N-acetyllactosamines, and sialyl-Lewis x (sLex) antigen. A clone permanently expressing an antisense fragment of beta 3Gal-T5 was obtained from the human pancreas adenocarcinoma cell line BxPC3 and characterized. Both beta 1,3Gal-T activity and sLea expression are dramatically impaired in the clone. Analysis of the oligosaccharides synthesized in cells metabolically labelled with tritiated galactose shows that a relevant amount of radioactivity is associated to large O-glycans. Endo-beta-galactosidase mostly releases NeuAc alpha 2-3Gal beta 1-3[Fuc alpha 1-4]GlcNAc beta 1-3Gal and NeuAc alpha 2-3Gal beta 1-3GlcNAc beta 1-3Gal from such O-glycans of BxPC3 membranes, but GlcNAc beta 1-3Gal and type 2 chain oligosaccharides, including NeuAc alpha 2-3Gal beta 1-4[Fuc alpha 1-3]GlcNAc beta 1-3Gal, from those of the antisense clone. Furthermore, BxPC3 cells secrete sLea in the culture media but not sLex, while antisense clone secretes mostly sLex, and accumulation of both antigens is prevented by benzyl-alpha-GalNAc. These data indicate that beta 3Gal-T5 suppression turns synthesis of type 1 chain O-glycans to poly N-acetyllactosamine elongation and termination by sLex. In other cell lines and clones, beta 3Gal-T5 transcript, beta 1,3Gal-T activity, and sLea antigen are also correlated, but quantitatively the relative expression ratios are very different from cell type to cell type. We suggest that beta 3Gal-T5 plays a relevant role in gastrointestinal and pancreatic tissues counteracting the glycosylation pattern associated to malignancy, and is necessary for the synthesis and secretion of CA19.9 antigen, whose expression still depends on multiple interacting factors.
我们研究了β1,3-半乳糖基转移酶(β1,3Gal-T)家族成员β3Gal-T5在癌症相关糖基化中的作用,重点关注唾液酸化路易斯a(sLea,CA19.9抗原的表位)、多聚N-乙酰乳糖胺和唾液酸化路易斯x(sLex)抗原的表达。从人胰腺腺癌细胞系BxPC3中获得了一个永久表达β3Gal-T5反义片段的克隆并进行了表征。在该克隆中,β1,3Gal-T活性和sLea表达均受到显著损害。对用氚标记的半乳糖进行代谢标记的细胞中合成的寡糖分析表明,相当数量的放射性与大的O-聚糖相关。内切β-半乳糖苷酶主要从BxPC3膜的此类O-聚糖中释放NeuAcα2-3Galβ1-3[Fucα1-4]GlcNAcβ1-3Gal和NeuAcα2-3Galβ1-3GlcNAcβ1-3Gal,但从反义克隆的O-聚糖中释放GlcNAcβ1-3Gal和2型链寡糖,包括NeuAcα2-3Galβ1-4[Fucα1-3]GlcNAcβ1-3Gal。此外,BxPC3细胞在培养基中分泌sLea但不分泌sLex,而反义克隆主要分泌sLex,并且苄基-α-GalNAc可阻止两种抗原的积累。这些数据表明,β3Gal-T5的抑制将1型链O-聚糖的合成转变为多聚N-乙酰乳糖胺的延伸并以sLex终止。在其他细胞系和克隆中,β3Gal-T5转录本、β1,3Gal-T活性和sLea抗原也相关,但在数量上,相对表达比率因细胞类型而异。我们认为,β3Gal-T5在胃肠道和胰腺组织中发挥着相关作用,可对抗与恶性肿瘤相关的糖基化模式,并且是CA19.9抗原合成和分泌所必需的,其表达仍取决于多种相互作用的因素。